Adjuvant Therapy of Primary Breast Cancer: Closing Summary

  • J. H. Glick
  • R. D. Gelber
  • A. Goldhirsch
  • H.-J. Senn
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 127)


Adjuvant therapy for stage I and II breast cancer remains in evolution as new data emerge from controlled randomized trials and from the overview analysis by the Early Breast Cancer Trialists’ Collaborative Group [4] (reprinted in part in this volume; referred to below as the Overview). The Fourth International Conference on Adjuvant Therapy of Primary Breast Cancer, held in St. Gallen, Switzerland, in February, 1992, brought together breast cancer experts from all over the world to present their most recent data and to discuss the remaining challenges that confront both clinicians and basic scientists.


Breast Cancer Adjuvant Therapy Primary Breast Cancer Early Breast Cancer Trialist Ovarian Ablation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    NIH Consensus Conference (1985) Adjuvant chemotherapy for breast cancer. JAMA 254:3461–3463CrossRefGoogle Scholar
  2. 2.
    NIH Consensus Conference (1991) Treatment of early-stage breast cancer. JAMA 265:391–395CrossRefGoogle Scholar
  3. 3.
    Glick JH (1988) Adjuvant therapy for breast cancer. J Nat Cancer Inst 80: 471–475PubMedCrossRefGoogle Scholar
  4. 4.
    Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75 000 women. Lancet 339:1–5, 71–85Google Scholar
  5. 5.
    Fisher B (1992) The recent NSABP experience and strategies. Proceedings of the 4th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. GallenGoogle Scholar
  6. 6.
    Rosen PP, Groshen S, Saigo PE et al. (1989) Pathological prognostic factors in stage I (T1 N0 M0) and stage II (T1 N1 M0) breast carcinoma. J Clin Oncol 7: 1239–1251PubMedGoogle Scholar
  7. 7.
    National Cancer Institute (1988) Clinical alert. National Cancer Institute, BethesdaGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1993

Authors and Affiliations

  • J. H. Glick
    • 1
  • R. D. Gelber
    • 2
  • A. Goldhirsch
    • 3
  • H.-J. Senn
    • 4
  1. 1.University of Pennsylvania Cancer CenterPhiladelphiaUSA
  2. 2.Dana Farber Cancer InstituteBostonUSA
  3. 3.Ospedale CivicoLuganoSwitzerland
  4. 4.Kantonsspital Oncology CenterSt. GallenSwitzerland

Personalised recommendations